ELIGARD 7.5 mg powder and solvent for solution for injection アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

eligard 7.5 mg powder and solvent for solution for injection

recordati industria chimica e farmaceutica spa - leuprorelin acetate - powder and solvent for solution for injection - 7.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

Depo-Eligard 22.5 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr. ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

depo-eligard 22.5 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr.

recordati industria chimica e farmaceutica s.p.a. - leuprorelin acetate 22,5 mg - eq. leuprorelin 20,87 mg - powder and solvent for solution for injection - 22,5 mg - leuprorelin acetate 22.5 mg - leuprorelin

Depo-Eligard 7.5 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr. ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

depo-eligard 7.5 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr.

recordati industria chimica e farmaceutica s.p.a. - leuprorelin acetate 7,5 mg - eq. leuprorelin 6,96 mg - powder and solvent for solution for injection - 7,5 mg - leuprorelin acetate 7.5 mg - leuprorelin

Depo-Eligard 45 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr. ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

depo-eligard 45 mg inj. sol. (pwdr. + solv.) s.c. pre-filled syr.

recordati industria chimica e farmaceutica s.p.a. - leuprorelin acetate 45 mg - eq. leuprorelin 41,7 mg - powder and solvent for solution for injection - 45 mg - leuprorelin acetate 45 mg - leuprorelin

LERIN leuprorelin (as acetate) 5 mg implant pre-filled syringe オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

lerin leuprorelin (as acetate) 5 mg implant pre-filled syringe

sandoz pty ltd - leuprorelin acetate, quantity: 5.25 mg (equivalent: leuprorelin, qty 5 mg) - implant - excipient ingredients: polylactic acid - palliative treatment of patients with advanced prostate carcinoma.

LERIN leuprorelin (as acetate) 3.6 mg implant pre-filled syringe オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

lerin leuprorelin (as acetate) 3.6 mg implant pre-filled syringe

sandoz pty ltd - leuprorelin acetate, quantity: 3.78 mg (equivalent: leuprorelin, qty 3.67 mg) - implant - excipient ingredients: polyglactin - palliative treatment of patients with advanced prostate carcinoma.

LUCRIN PDS DEPOT 11.25 MG イスラエル - 英語 - Ministry of Health

lucrin pds depot 11.25 mg

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - powder and solvent for suspension for injection - leuprorelin acetate 11.25 mg - leuprorelin - endometriosis, prostatic cancer, treatment of uterine fibroids for a period of up to six months. treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.

LUCRIN PDS DEPOT 11.25 MG イスラエル - 英語 - Ministry of Health

lucrin pds depot 11.25 mg

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - powder and solvent for suspension for injection - leuprorelin acetate 11.25 mg - leuprorelin - endometriosis, prostatic cancer, treatment of uterine fibroids for a period of up to six months. treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.

LUCRIN PDS DEPOT 3.75 MG イスラエル - 英語 - Ministry of Health

lucrin pds depot 3.75 mg

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - powder and solvent for suspension for injection - leuprorelin acetate 3.75 mg - leuprorelin - endometriosis prostatic cancer treatment of uterine fibroids for a period of up to six months. treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.

LUCRIN PDS DEPOT 3.75 MG イスラエル - 英語 - Ministry of Health

lucrin pds depot 3.75 mg

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate - powder and solvent for suspension for injection - leuprorelin acetate 3.75 mg - leuprorelin - endometriosis prostatic cancer treatment of uterine fibroids for a period of up to six months. treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.